News & Updates
Showing Oncology articles
Showing
Patritumab deruxtecan may improve survival in EGFR-mutated NSCLC
Treatment with patritumab deruxtecan (HER3-DXd) confers survival benefits on patients with epidermal growth factor receptor (EGFR)-mutated nonsmall-cell lung cancer (NSCLC) following EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy, results of a phase I study have shown.
Could 15 years be the new 10 for repeat colonoscopy?
Adults who have tested negative for colorectal cancer (CRC) on initial colonoscopy and have no family history of CRC may only need to undergo a repeat screening after 15 years, according to a new Swedish study.
Olanzapine vs fosaprepitant: Which is better for CINV prevention?
Olanzapine appears to be just as effective as fosaprepitant, a neurokinin-1 receptor antagonist (NK1-RA), in controlling chemotherapy-induced nausea and vomiting (CINV) in patients with gynaecologic malignancies who were receiving carboplatin/paclitaxel chemotherapy every 3 weeks, a prospective study presented at SGO 2024 suggests. However, the former trumps the latter in terms of cost effectiveness.
More evidence supports enzalutamide’s link with poorer mood and cognitive outcomes in mCRPC
Patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide reported more fatigue, depression and deterioration in perceived cognitive ability, and slower reaction time than those receiving abiraterone acetate, according to results of the ACE study.
